



ASX AND MEDIA RELEASE

Peplin to present at the BIO Emerging Company Investor Forum

BRISBANE, Australia, 12 October 2004: Peplin Limited (ASX: PEP) is presenting at the BIO Emerging Company Investor Forum this week in San Francisco, California.

Sponsored by the US Biotechnology Industry Organisation (BIO), the event is exclusively focused on the most promising public and late-stage private companies in the biotechnology industry.

Peplin CEO and Managing Director Michael Aldridge said the invitation to present at the forum provided an attractive opportunity for Peplin to highlight its investment potential to US investors.

“Presenting at the forum allows us to showcase Peplin in front of an audience of the biotechnology industry’s most active and prominent institutional investors and pharmaceutical companies both in the US and internationally,” he said.

Mr Aldridge will present at the forum on Wednesday 13 October 2004 at 11:50 a.m. local time (Thursday 14 October at 4:50 a.m. Australian Eastern Time). The presentation will be webcast and can be viewed via Peplin’s website.

To access the live presentation or a subsequent archived recording, please log onto Peplin’s website at www.peplin.com and activate the webcast link which can be found under the “Investor Information – Investor Briefings” section. The archived webcast will be available from two hours after the live presentation.

The presentation material will be available on Peplin’s website from Wednesday.

ABOUT PEPLIN

Peplin is focused on the discovery, development and commercialisation of prescription human therapeutic products for the treatment of cancer. Peplin’s strategy is to leverage its pipeline of novel proprietary products through collaborative development and commercialisation arrangements with international pharmaceutical companies.

Peplin’s lead product is a potential topical therapy (PEP005 Topical) for actinic keratosis and non-melanoma skin cancer. Peplin holds global rights for PEP005 Topical and all rights worldwide to other oncology applications of PEP005.

Peplin’s earlier stage pipeline is targeted at bladder cancer using PEP005 in an intracavity or intravesical formulation (PEP005 IC) and leukaemia (a blood borne cancer) using an intravenous formulation (PEP005 IV). Its portfolio of EPUFA compounds opens additional potential opportunities in cancer and adds candidates for cardiovascular disease, pain, inflammation and diabetic complications.

Further information on Peplin:

Michael Aldridge
Managing Director & CEO
Tel: 07-3250-1200
michael.aldridge@peplin.com

Media enquiries:

Stephanie Paul
PhillipsGroup
Tel: 07-3230 5000
spaul@phillipsgroup.com.au